Over the past few years, major changes have taken place in the treatment of gastroduodenal peptic ulcer.
Dr Giorgio Talamini and colleagues evaluated risk factors associated with the incidence of peptic ulcer in inpatients.
The team monitored the number of prescriptions of H2-antagonists and proton pump inhibitors in each department of Verona University Hospital from 2001 to 2004.
|Proton pump inhibitor use was predictive of duodenal ulcer|
|Journal of Clinical Gastroenterology|
Over the same period the researchers prospectively recorded the number of upper endoscopies per department for inpatients with a diagnosis of peptic ulcer.
The researchers analyzed 4,943 inpatients.
A significantly decreasing trend in H2-antagonist prescriptions, and an increasing trend in proton pump inhibitor prescriptions were observed.
The research team found that the endoscopic incidence of duodenal ulcers decreased linearly from 7% in 2001 down to 3% in 2004.
The team found that gastric ulcer incidence, sex, age, indication for endoscopy, and use of nonsteroidal anti-inflammatory drugs showed no changes over the study period.
The presence of Helicobacter pylori, and smoking and drinking habits showed no significant changes over the study period.
Considering time-dependent variables, multivariate regression analysis identified proton pump inhibitor use as predictive of duodenal ulcer but not of gastric ulcer.
In addition, nonsteroidal anti-inflammatory drugs use was a factor predictive of duodenal ulcer but not of gastric ulcer.
Dr Talamini‘s team concluded, "In inpatients, proton pump inhibitors are associated with a reduced risk of duodenal ulcer, whereas nonsteroidal anti-inflammatory drugs are associated with an increased risk."
"Gastric ulcer was not associated with any increased or degreased risk with the 2 above-mentioned variables."